Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= Overview =
6	6
7		-Organovo Holdings, Inc. is an early commercial stage company focused on developing and commercializing functional three-dimensional (“3D”) human tissues. Using its proprietary technologies and expertise in bioprinting, Organovo Holdings is building functional 3D human tissues that mimic key aspects of native biology, and can be used in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. Organovo Holdings is utilizing its proprietary bioprinting platform to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Organovo Holdings is leveraging its unique tissue models to improve the current industry standard cell-based and animal model testing approaches, and the company believe its foundational approach provides it with the opportunity to fill many critical gaps in commercially available preclinical human tissue models as well as in tissue transplantation. Specifically, Organovo Holdings is focused on developing the following offerings:
	7	+Organovo Holdings, Inc. (ONVO) is an early commercial stage company focused on developing and commercializing functional three-dimensional (“3D”) human tissues. Using its proprietary technologies and expertise in bioprinting, Organovo Holdings is building functional 3D human tissues that mimic key aspects of native biology, and can be used in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. Organovo Holdings is utilizing its proprietary bioprinting platform to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Organovo Holdings is leveraging its unique tissue models to improve the current industry standard cell-based and animal model testing approaches, and the company believe its foundational approach provides it with the opportunity to fill many critical gaps in commercially available preclinical human tissue models as well as in tissue transplantation. Specifically, Organovo Holdings is focused on developing the following offerings:{{footnote}}https://fintel.io/doc/sec-onvo-organovo-holdings-10k-annual-report-2018-may-31-17978{{/footnote}}
8	8
9	9	* A suite of standardized, 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (“ADME”), and drug metabolism and pharmacokinetics (“DMPK”);
10	10	* Highly customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development and disease modeling; and
...	...	@@ -82,11 +82,11 @@
82	82
83	83	Implantable 3D Tissues for Clinical Use: This aspect of its business involves application of its 3D bioprinting technology to generate human tissues suitable for implantation in vivo to augment or replace damaged or degenerating tissues. These efforts will be undertaken by it alone, or as partnered projects with leading therapeutic companies seeking to develop a therapeutic tissue product for a specific application. Near-term revenues would come from the funding of development work and, in some cases, licensing fees for access to its platform technologies. The company expect longer-term revenues may arise from shared profits and royalties or other forms of income from successful clinical and commercial development of the tissue products. There are many companies pursuing the discovery, development, and commercialization of tissue-based products for a variety of applications, including but not limited to Organogenesis and Cyfuse. These companies uniquely represent potential competition for it while also being partner candidates. Its platform has the ability to enable the generation and optimization of unique, scaffold-free or hybrid tissue prototypes and ultimately support production of the tissue.
84	84
85		-==== Research and Development ====
	85	+= Research and Development =
86	86
87	87	The company continuously engage in research and development to enhance its platform technology, to develop new products and service offerings and to pursue its therapeutic initiatives. Its research and development efforts include internal initiatives as well as collaborative development opportunities with third parties. Its research and development expenses were $19.5 million, $18.0 million and $12.9 million for the fiscal years ended March 31, 2017, March 31, 2016, and March 31, 2015, respectively. The company focus its research and development activities in areas where Organovo Holdings has technological expertise and where the company believe a significant market opportunity exists for its technology and the products and services the company develop. The company intend to continue its focus on research and development as a key strategy for the growth of its business.
88	88
89		-==== Intellectual Property ====
	89	+= Intellectual Property =
90	90
91	91	HTG Molecular's success depends in large part on its ability to establish and protect its proprietary bioprinting technologies and its engineered tissue products and services. The company rely on a combination of patents, trademarks, trade secrets, confidential know-how, copyrights and a variety of contractual mechanisms such as confidentiality, material transfer, licenses, research collaboration, limited technology access, and invention assignment agreements, to protect its intellectual property. Its intellectual property portfolio for its core technology was initially built through licenses from the University of Missouri-Columbia (“MU”) and the Medical University of South Carolina. Organovo Holdings has subsequently expanded its intellectual property portfolio by filing patent and trademark applications worldwide and negotiating additional licenses and purchases.
92	92
...	...	@@ -129,3 +129,5 @@
129	129	As June 1, 2017, Organovo Holdings has 113 full-time employees. The company also engage consultants and temporary employees from time to time to provide services that relate to its bioprinting business and technology as well as for general administrative services.
130	130
131	131	= References =
	132	+
	133	+{{putFootnotes/}}